• Login
    • Advanced search
    • Title
    • Channel
    • Module
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive and Mobility
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transportation and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
Hogan Lovells Engage 5.7.22
      • Title
      • Channel
      • Module
    • Hit ENTER to search in content
    • Advanced search
    • Login
  • Home
  • Industry
    •  

      • Aerospace, Defense, and Government Services
      • Automotive and Mobility
      • Consumer
      • Manufacturing and Industrials
      • Education
      • Energy and Natural Resources
      • Financial Institutions
    •  

      • Insurance
      • Life Sciences and Health Care
      • Private Capital
      • Real Estate
      • Sports, Media and Entertainment
      • Technology and Telecoms
      • Transportation and Logistics
  • Practice
    • Corporate & Finance

      • Banking and Loan Finance
      • Business Restructuring and Insolvency
      • Capital Markets
      • Corporate Governance and Public Company Representation
      • Digital Assets and Blockchain
      • Infrastructure, Energy, Resources, and Projects
      • Leveraged and Acquisition Finance
      • Mergers and Acquisitions
      • Pensions
      • Private Equity, Venture Capital and Investment Funds
      • Real Estate
      • Real Estate Investment Trusts (REITs)
      • Tax
      • Transfer Pricing
    • Global Regulatory

      • Administrative and Public Law
      • Antitrust and Competition
      • Communications, Internet, and Media
      • Education
      • Energy Regulatory
      • Environment and Natural Resources
      • Financial Services
      • Food Law
      • Gaming Law
      • Government Contracts and Public Procurement
      • Government Relations and Public Affairs
      • Health
      • Immigration
      • International Trade and Investment
      • Medical Device and Technology Regulatory
      • New Nuclear
      • Pharmaceuticals and Biotechnology Regulatory
      • Privacy and Cybersecurity
      • Space and Satellite
      • Strategic Operations, Agreements and Regulation
      • Transportation Regulatory
    • Intellectual Property

      • Copyright
      • Designs
      • Domain Names
      • IP and Technology Transactions
      • IP Enforcement
      • Patents
      • Trade Secrets and Confidential Know-how
      • Trademarks and Brands
      • Unfair Competition
    • Litigation, Arbitration, and Employment

      • Business and Human Rights
      • Construction and Engineering
      • Corporate and Securities Litigation
      • Employment
      • International Arbitration
      • Investigations, White Collar, and Fraud
      • Products Law
      • Risks, Disputes, and Litigation
  • Comparative guides
  • Engage Premium
  • Login
  • Register
  1. News
  2. Restrictions on lawyer ads involving drugs and medical devices are not unconstitutional, says federal court

Restrictions on lawyer ads involving drugs and medical devices are not unconstitutional, says federal court

18 May 2022
    • Share by email
    • Share on
    • Twitter
    • LinkedIn
    • Get link
    • Get QR Code
    • Download
    • Print

The Fourth Circuit has found that a West Virginia state law restricting how attorneys can solicit clients in pharmaceutical and medical device cases does not violate the First Amendment. At the end of April, a three-judge panel reversed a lower court ruling that had handed summary judgment to two personal injury lawyers and their client in their suit that alleged the law was unconstitutional.

Recently, in Recht v. Morrisey, the Fourth Circuit rebuffed a First Amendment challenge to a West Virginia law that places restrictions on legal advertisements soliciting clients for lawsuits regarding the use of prescription drugs and medical devices.1 We’ve all seen these advertisements on TV – a lawyer announces that a particular drug or medical device is potentially causing harm, and urges users of the product to join a lawsuit against the manufacturer. A growing focus in recent years, however, has been on the potential harm from the advertisements themselves. In 2019, the Federal Trade Commission (FTC) sent letters to seven legal practitioners and lead generators expressing concern that these advertisements “may be deceptive or unfair under the FTC Act.”2 The FTC noted that the Food and Drug Administration (FDA) had received reports of “consumers who saw lawsuit ads about the prescription drugs they were taking, discontinued those medications, and suffered adverse consequences as a result.”

In response to concerns over these advertisements, West Virginia passed a law in 2020 – the Prevention of Deceptive Lawsuit Advertising and Solicitation Practices Regarding the Use of Medications Act (the “Act”) – prohibiting certain legal advertising practices and requiring disclosures and warnings for the protection of patients.3 The requirements of the Act are intended to prevent these legal advertisements from being misrepresented as professional, medical, or government agency advice about prescription drugs or medical devices. Among other requirements, the Act states these advertisements must specifically disclose that they are “paid advertisement[s] for legal services,” to identify the sponsor of the advertisement and the attorney or law firm that will represent clients, and to warn viewers against discontinuing use of FDA-approved drugs or medical devices without consulting with their doctors.

Shortly after the Act was passed, it was challenged by two plaintiffs' attorneys in court on First Amendment grounds. The District Court for the Northern District of West Virginia held for the plaintiffs, and permanently enjoined and prohibited West Virginia from enforcing the Act. On appeal, however, the Fourth Circuit reversed the District Court’s decision.4 The technical legal issue was whether the Act was within the bounds of permissible regulation of commercial speech. The Fourth Circuit opinion concludes that the Act “survives constitutional challenge” and works to “protect the health of West Virginia citizens who may be misled into thinking that attorneys are reliable sources of medical advice.” Although the plaintiffs have indicated they intend to appeal the decision,5 with the Act having survived this initial “constitutional challenge,” we may see more efforts in other states to enact similar laws placing restrictions on lawsuit advertisements involving drugs and medical devices.6

 

 

Authored by Lauren Colton, Philip Katz, Bert Lao, and Julie Schindel.

References
1 No. 21-1684, 2022 WL 1233240 (4th Cir. Apr. 27, 2022).
2 Federal Trade Commission, FTC Flags Potentially Unlawful TV Ads for Prescription Drug Lawsuits (Sept. 24, 2019), https://www.ftc.gov/news-events/news/press-releases/2019/09/ftc-flags-potentially-unlawful-tv-ads-prescription-drug-lawsuits.
3 W. Va. Code §§ 47-28-1 et seq.
4 Recht, 2022 WL 1233240.
5 See B. Pierson, State law restricting attorneys' drug ads revived by 4th Circuit, Reuters (Apr. 27, 2022), https://www.reuters.com/legal/litigation/state-law-restricting-attorneys-drug-ads-revived-by-4th-circuit-2022-04-27/.  Indeed, on May 10, 2022, Plaintiffs filed a petition for rehearing en banc urging the full Fourth Circuit to rethink the panel’s decision. See Attys Urge 4th Circ. To Revisit W.Va. Law On Drug Case Ads - Law360
6 Other states, including Tennessee and Texas, already have similar statutes in place. See id.
Contacts
Lauren Colton
Partner
Baltimore
Philip Katz
Partner
Washington, D.C.
Bert Lao
Counsel
Los Angeles
Julie Schindel
Senior Associate
Baltimore
Related Materials
Sanctions Navigator

Sanctions Navigator: Russia Sanctions

Languages English
Topics Cell, Tissue, and Gene Therapies (CTGT), Clinical Trials, Combination Products, Digital Health, Life Science Government Enforcement and Compliance, Advertising and Promotion of Medical Devices, Clinical Studies/Product Design and Development, Conformity Assessment Procedure/CE Mark, In Vitro Diagnostics, MDR/IVDR, Medical Device Software and Cybersecurity, Postmarket Performance, Premarket Strategy, Submissions, and Review, Regulatory Inspections and QSR/ISO 13485, State Licensing of Medical Device, Advertising and Promotion of Pharmaceuticals and Biotechnology, Biologics and Biosimilars, Controlled Substances, Life Cycle Management of Pharmaceuticals and Biotechnology, OTC Drugs and Cosmetics, Regulatory Exclusivities, Hatch-Waxman, and Similar Statutes, Regulatory Inspections and cGMP, Products Law, U.S. Appellate and Supreme Court Litigation
Countries United States
Delete Comment ?

Are you sure want to delete comment ?

Get link
Embed
Share by email
Get QR Code

Scan this QR Code to share this content

  • Contact us
  • Disclaimer
  • Privacy
  • Cookies
  • Legal Notices
  • Terms of Use

 

This website is operated by Hogan Lovells International LLP, whose registered office is at Atlantic House, Holborn Viaduct, London, EC1A 2FG. For further details of Hogan Lovells International LLP and the international legal practice that comprises Hogan Lovells International LLP, Hogan Lovells US LLP and their affiliated businesses ("Hogan Lovells"), please see our Legal Notices page. © 2022 Hogan Lovells.

Attorney advertising. Prior results do not guarantee a similar outcome.

Thomson Reuters HighQ Logo
© 2023 Hogan Lovells | Privacy Policy | Terms of Service